Earnings
Biogen revenue climbs, while Spinraza, Tecfidera sales miss
Drug developer Biogen reported a 11.4 percent rise in quarterly revenue as sales of key drugs Tecfidera and Spinraza climbed, albeit at a weaker-than-expected pace. The company’s top-earning multiple sclerosis drug Tecfidera brought in a […]